Literature DB >> 15768028

Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Cédric Raoul1, Toufik Abbas-Terki, Jean-Charles Bensadoun, Sandrine Guillot, Georg Haase, Jolanta Szulc, Christopher E Henderson, Patrick Aebischer.   

Abstract

Mutations in Cu/Zn superoxide dismutase (encoded by SOD1), one of the causes of familial amyotrophic lateral sclerosis (ALS), lead to progressive death of motoneurons through a gain-of-function mechanism. RNA interference (RNAi) mediated by viral vectors allows for long-term reduction in gene expression and represents an attractive therapeutic approach for genetic diseases characterized by acquired toxic properties. We report that in SOD1(G93A) transgenic mice, a model for familial ALS, intraspinal injection of a lentiviral vector that produces RNAi-mediated silencing of SOD1 substantially retards both the onset and the progression rate of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15768028     DOI: 10.1038/nm1207

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  155 in total

Review 1.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

2.  IFNγ triggers a LIGHT-dependent selective death of motoneurons contributing to the non-cell-autonomous effects of mutant SOD1.

Authors:  J Aebischer; P Cassina; B Otsmane; A Moumen; D Seilhean; V Meininger; L Barbeito; B Pettmann; C Raoul
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

Review 3.  RNA-targeted Therapeutics for ALS.

Authors:  Linga V Reddy; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

4.  Exploring the zebra finch Taeniopygia guttata as a novel animal model for the speech-language deficit of fragile X syndrome.

Authors:  Claudia Winograd; Stephanie Ceman
Journal:  Results Probl Cell Differ       Date:  2012

5.  Optimization of feline immunodeficiency virus vectors for RNA interference.

Authors:  Scott Q Harper; Patrick D Staber; Christine R Beck; Sarah K Fineberg; Colleen Stein; Dalyz Ochoa; Beverly L Davidson
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 6.  RNA interference in neuroscience: progress and challenges.

Authors:  Victor M Miller; Henry L Paulson; Pedro Gonzalez-Alegre
Journal:  Cell Mol Neurobiol       Date:  2005-12       Impact factor: 5.046

Review 7.  Silence of the transcripts: RNA interference in medicine.

Authors:  Sailen Barik
Journal:  J Mol Med (Berl)       Date:  2005-07-19       Impact factor: 4.599

Review 8.  The potential application of gene therapy in the treatment of traumatic brain injury.

Authors:  Fang Shen; Liang Wen; Xiaofeng Yang; Weiguo Liu
Journal:  Neurosurg Rev       Date:  2007-08-09       Impact factor: 3.042

Review 9.  Applications of lentiviral vectors for shRNA delivery and transgenesis.

Authors:  Oded Singer; Inder M Verma
Journal:  Curr Gene Ther       Date:  2008-12       Impact factor: 4.391

Review 10.  High content analysis in amyotrophic lateral sclerosis.

Authors:  Federica Rinaldi; Dario Motti; Laura Ferraiuolo; Brian K Kaspar
Journal:  Mol Cell Neurosci       Date:  2016-12-11       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.